EARLIER STUDIES on the metabolism of folic acid by man, using 3H-labelled tracers (Chanarin & McLean, 1967) or microbiological assay (Ratanasthien, 1 975) , yielded conflicting results. There have been no detailed studies since the introduction of the unambiguous technique of using a mixture of 14C-and 3H-labelled species by ourselves, and the recognition of a breakdown process as a major route of metabolism of folates in the rat (Murphy et al., 1976; Connor et al., 1979) .
It is believed that two pools of folate exist in the rat; a short-term pool of folate monoglutamates giving p-acetamidobenzoate as a urinary catabolite, and a long-term pool of folate polyglutamates giving p-acetamidobenzoyl-L-glutamate . The identification of 14C-labelled pterins in the urine of one human subject given 14C-folic acid (Krumdieck et al., 1978) and 3H-p-acetamidobenzoyl-L-glutamate in the urine of a limited number of subjects given 3H-+14C-labelled folic acid , together with the pattern of excretion of radioactivity in these experiments, suggest that the same metabolic pools and catabolic routes may exist in man.
Folates are essential for cell division, and folate status is therefore important in malignant disease. Folate deficiency is associated with malignant disease (Blakley, 1969; Chanarin, 1979) but no detailed comparative metabolic studies have been carried out in man. Catabolism of folate in the rat has recently been shown to be reduced in the presence of a tumour (Saleh et al., 1981) . Therefore the metabolism of a mixture of 14C-and 3H-labelled folic acid was studied in control patients and in patients with malignant disease in order to observe any metabolic variations which may have diagnostic or therapeutic applications. Preliminary results have been reported elsewhere (Saleh et al., 1980) . 10-Formylfolate, an oxidized folate, is an important constituent of food folate (Butterworth et al., 1965; Santini et al., 1964) . However, it is not reduced by Ehlrich ascites carcinoma (Bertino et al., 1965) or bovine dihydrofolate reductase (A. Sahota, personal communication) and therefore may not be available to mammals. Earlier investigations by Ratanasthien et al. (1974) , using a microbiological assay, showed no metabolism of orally administered 10-formylfolate by man. However, Pheasant et al. (1981) found that radiolabelled 10-formylfolate was incorporated into the reduced folate pool of the rat. Further studies undertaken using radiolabelled 10-formylfolate in man, to resolve these apparent discrepancies, are described here.
MATERIALS AND METHODS

Experimental design
Patients.-The study was carried out on hospital inpatients (General Hospital, Birmingham) suffering from malignant disease or other disorders. Details of the patients may be found in Table I . All patients were allowed a normal diet throughout the experiment. Informed consent was obtained from all participants.
Metabolism of folic acid.-Two groups of patients were used: Group I-I patients suffering from malignant disease; Group II.-6 patients suffering from other disorders as controls. All patients were given an oral dose of a mixture of 5 uCi uCi [3', 5', 7, folic acid plus 5 mg unlabelled folic acid.
Metabolism of 10-formylfolic acid and its effect on folic acid metabolism.-Three groups of 3 control patients were used:
Group III.-Patients were given a mixture of [2-14C] folic acid + [3', 5', 7, 9-3H] folic acid (60 ,tg).
Group IV.-Patients were given a mixture of [2-14C] + [3', 5', 7, 9-3H] 10-formylfolic acid + 5 mg unlabelled 10-formylfolic acid.
Group V.-Patients were given a mixture of [2-14C] + [3', 5', 7, 9-3H] folic acid (60 ,ug) + 5 mg unlabelled 10-formylfolic acid.
Urine and faeces collection Urine was collected on sodium ascorbate (10 g) for the following periods; 0-6 h, 6-12 h and 12-24 h after administration of the dose. Urine volumes were measured for each period, and samples kept frozen at -200C until analysis, which was within a week of collection. In some cases faeces were collected in a plastic bag, which was closed with a rubber band and put into an air-tight container.
Determination of radioactivity
Urine samples and column effluents were counted as described in Connor et al. (1979) . Faeces were freeze-dried and ground to give a homogeneous powder; 100mg samples were used to estimate total radioactivity as described by Barford et al (1978) .
Chromatography
Sephadex G15 gel filtration and DEAEcellulose chromatography (using linear gradients of 0-1 2M NaCl in 0-05M sodium phosphate buffer, pH 7 0) were performed as described previously (Barford et al., 1977) . Paper chromatography was performed as described by Connor et al. (1979) .
Chemicals
All chemicals used were of Analar grade or its equivalent. [2-14C] Folic acid (sp. 50 mCi/ mmol) and (3', 5', 7, 9-3H] folic acid (sp. 500 mCi/mmol) were obtained from the Radiochemical Centre, Amersham, Bucks. p-Acetamidobenzoyl-L-glutamate was prepared as described in Baker et al. (1964) . 10-Formylfolic acid was synthesized from folic acid (Blakley, 1959) , and [2-14C] and [3', 5', 7, 9-3H) 10-formylfolic acid was prepared as follows: a solution of [2-14C] folic acid (50 ,uCi, 52-4 mCi/mmol) and [3', 5', 7, 9-3H] folic acid (250 ,uCi, 500 mCi/mmol) was dissolved in 0-8 ml of distilled formic acid (98%). After storage of the solution in the dark at room temperature for 48 h, the excess formic acid was removed by freeze-drying. Chromatography of the product on DEAE-cellulose gave a single radioactive peak at 0-53M NaCl, co-chromatographing with authentic 10-formylate (folic acid elutes at 0-96M NaCl).
RESULTS
Metabolism of folic acid
The urinary recoveries of radioactivity after an oral dose of labelled folic acid (5 mg) are shown in Table II . There is a discrepancy between the recovery of 3H and 14C in the urine. Urinary recovery of 3H was significantly higher than 14C in [3', 5', 7, 9-3H] folic acid (5 my). The 3H  14C  3H  14C  3H  14C  3H  14C 23-8 20-4 4-6 3-7 1-6 0-2 15-1 14-6 8-4 8-0 2-1 2-2 0-3 0-2 15-0 12-0 7-0 6-0 12-3 10-4 7 0 5-9 2-4 1-7 14-7 13-2 3-6 3-1 0-9 0-5 %Dose recovered 3H 14C
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10-3 26-6 0-2 0-3 both groups of patients, when determined by a paired t test (P < 0-001). Cancer patients excreted significantly less radioactivity in urine than control patients (P< 0001); 14.1% 3H, 12.4% 140 and 32.0% 3H and 26.2% 14C of the dose being excreted in the urine of cancer patients and control patients, respectively. Most of the radioactivity appearing in the urine was excreted in the first 12 h by both groups of patients. Excreted radioactivity fell rapidly on the second day, but was detected at low levels in the urine up to 5 days. The urinary recovery of the individual cancer patients showed an inverse correlation between total urinary recovery and size of tumour. The urinary recovery decreased as the approximate size and extent of the tumour mass, as judged by the clinician, increased, indicating a larger requirement for folate in malignant disease. Table III shows the recovery of 3H and 14C in the faeces; where more 14C than 3H was present. No evidence for malabsorption of folate in malignant disease was apparent from these investigations.
Urinary metabolites
Urine samples were sequentially chromatographed on DEAE-cellulose, Sephadex G15 and paper. In all cases, this revealed a number of radioactive components. Three of the components detected in the urine retained the 3H-and 14C-label in the same ratio, and were identified by co-chromatography with authentic standards in both column systems as folic acid, 5-methyl- tetrahydrofolate (5MeTHF) and 10-formylfolate. The ratio 3H/14C in these folate derivatives was higher than in the folic acid administered. The remaining components detected in the urine of both groups were catabolites, labelled solely with 3H or mainly with 14C. The 3H-catabolites were identified as p-acetamidobenzoyl-L-glutamate, p-acetamidobenzoate and water. The 14C-labelled catabolite has not been identified. It eluted from both columns in the position of metabolite B which has been recently reorted in rat urine (Saleh et al., 1981) . Table IV summarizes the relative distribution of the major metabolites appearing in the various urine samples of both groups of patients. Cancer patients excreted significantly less unchanged folic acid than control patients (0 01 < P < 0 05). There is no significant difference in 5MeTHF excretion between the two groups, but the ratio of folic acid to 5MeTHF decreased considerably with time in cancer patients, whereas it decreased only slightly in control patients (folic acid/5MeTHF for 0-6 h, 6-12 h, and 12-24 h; 5-2, 3 1, 1 0 for Group I; 5-6, 5,1, 2-8 for Group II). Urinary scission product excretion relative to intact folates increased with time in both groups. However, total scission products were significantly decreased in cancer patients (0.01 <P< 0.05). p-Acetamidobenzoate was not present in 0-6h urine samples of either group and appeared in the 6-1 2h urine sample of most cancer patients but only one control patient (E.W.). Its excretion was maximal in the 12-24h urine samples of both groups. pAcetamidobenzolyl-L-glutamate showed a reciprocal pattern: it was maximal in the first urine samples (0-6 h) and decreased slowly as a percentage of the dose thereafter. Overall, p-acetamidobenzoyl-Lglutamate excretion was significantly depressed in cancer patients (P < 0.05), whereas p-acetamidobenzoate excretion was unchanged. Metabolism of 10-formylfolic acid and its effect on folic acid metabolism Group III: Metabolism of folic acid (60 ,ug).-2.6% of 3H and 1.8% of 14C of the dose were excreted in the urine in 24 h by control subjects receiving 60 ,ug folic acid (Table V) , and 1.7% 14C and 1.3% of 3H were recovered in their faeces in 48 h. Thus at this lower dose of folic acid a much Group V* M.F. 10-0 9 9 0 9 0 9 0.5 0.5 S.H.
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The results are expressed as the percentage of the dose present as each metabolite. * As in Table V . t 0-6 h only.
greater proportion of the dose was retained in the body than in the 5mg dose. Chromatographic analysis of the urine samples showed that radioactivity in the urine from subjects given the low dose was present only as scission products. No folic acid was detected in the urine and little or no 5MeTHF. The major urinary catabolite was labelled only with 3H and identified as p-acetamidobenzoyl-L-glutamate. p-Acetamidobenzoate was also detected. The 14C-labelled species was different from that found earlier, and remains unidentified. Group IV: Metabolism of 10-formylfolic acid.-The urinary recovery of the radioactivity in 24 h after the administration of [2-14C] + [3',5',7,93H] 10-formylfolic acid is given in Table V . 49-1% of 3H and 45.2% of 14C of the dose were recovered in 24 h in the urine. Excretion of radioactivity in the urine was maximal in the first period and dropped sharply thereafter. Urine samples were sequentially chromatographed on DEAE-cellulose and Sephadex GI5, and this revealed a number of radioactive components. More than 90% of the urinary radioactivity was identified as 10-formylfolic acid. The other metabolites detected in the urine were folic acid, 5-MeTHF and a very small amount of 3H-labelled catabolites. More folic acid was excreted than 5MeTHF, but the total amount of both did not exceed 3%1 of the dose (Table VI) . (Table V) . The recovery of 3H and 14C, in individual samples were quite similar, particularly in the 0-6 and 6-12h urine samples. Table VI shows the distribution of radiolabelled folate derivatives in the urine 12 h after the administration of the dose. The major urinary radioactive product was unmetabolized folic acid.
DISCUSSION
This study shows that orally administered folic acid is incorporated into the reduced folate pool, and confirms the existence of a breakdown process in man similar to that elucidated in the rat . The control subjects excreted a large proportion of the dose unchanged and, unlike the rat, the excretion of folic acid continued throughout the experiment. The folates present in the urine had a higher 3H/14C ratio than the administered folic acid (see Table IV ), indicating that the secondary isotope effect seen in the handling of labelled folic acid by the rat (Connor et al., 1980 ) also occurs in other species. The same catabolites were identified in the urine of man and rat, but the order of appearance of the two major tritiated species was reversed. If the radioactivity not recovered in the urine or faeces is retained in the tissues, man excretes a higher percentage of the tissue folates as scission products than the rat (Table IV) . This is consistent with the suggestion that catabolism proceeds via oxidative cleavage on the C9-NIO bond (Murphy et al., 1976; Saleh et al., 1981 since the hepatic NAD/NADH ratio is higher in man than rat (R. A. Harris, personal communication).
Patients with malignant disease excreted less radioactivity in the urine. Intestinal malabsorption of folate is not usually associated with neoplasia (Chanarin, 1979) and, by analogy with the rat, the remaining radioactivity is presumably taken up into tumour tissue (Saleh et al., 1981) . This is supported by the inverse correlation between the approximate tumour mass and urinary radioactivity. These patients also incorporated more of the administered folic acid into the reduced folate pool, as shown by the decreased excretion of folic acid and the reduced folic acid/5MeTHF ratio (Table IV) , changes which all become more pronounced in the more advanced cases. These results reflect the increased requirement for folate in malignant disease, arising from presence of an additional cell mass.
Despite the increased incorporation of the labelled folate into the reduced folate pool, lower levels of labelled p-acetamidobenzoyl-L-glutamate, the catabolite of the folate polyglutamates, were excreted in the urine (Table IV) . This apparent decrease in the catabolism of tissue folate in the presence of a tumour has also been observed in rats, and it has been suggested that it is due to the anoxia of solid tumours, and to the more reducing conditions prevailing in the cytosol of tumour cells (Saleh et al., 1981) .
Administered 10-formylfolate (5 mg) was excreted largely unchanged. Approximately 10% of the dose was excreted as 5MeTHF, and a small proportion was present as catabolites (Table VI) . This indicates very slow incorporation of 10-formylfolate into the reduced folate pool. The presence of folic acid in the urine suggests that deformylation may precede reduction. Indeed, the folic acid/5MeTHF ratio was similar to that after the administration of folic acid to control subjects. By analogy with folic acid, some of the dose may have been excreted in the faeces and possibly a small percentage retained in the body. The retained radioactivity may reflect the metabolism of that proportion of the dose that was deformylated to folic acid. Thus it appears that in contrast to the rat, 10-formylfolate is utilized only poorly by man, and is probably not reduced to any significant extent in the human body.
Decreasing the dose of folic acid to I 0 mg or 0 5 mg has been shown to lead to lower recovery of radioactivity in urine, with a greater fall in excretion of folic acid than of the other metabolites (Saleh et al., 1980) . In this study a dose about equal to the daily intake of folate was given (60 ,g) and the results confirmed the observations of Pheasant et al. (1979) . At this low dose, little or no folate was excreted and the only detectable metabolites were scission products. The low recovery of radioactivity in the urine probably indicates that the renal threshold for folates (Johns et al., 1961) has not been exceeded, whereas the catabolites appear to have much lower renal thresholds.
The pattern of urinary metabolites altered dramatically when the same low dose of radiolabelled folic acid was given along with 10-formylfolate (5 mg). A substantial proportion of the folic acid was rapidly excreted unchanged, and relatively little 5MeTHF or scission products were formed. 10-Formylfolate is known to inhibit the reduction of folic acid and dihydrofolate by mammalian dihydrofolate reductase (E.C. 1.5.1.3) in vitro (Bertino et al., 1965; Friedkin et al., 1975; A. Sahota, personal communication) . These observations suggest that 10-formylfolate also effectively blocks the reduction of folic acid in vivo. Hence 10-formylfolate present in the diet, or formed in the body by the oxidation of 10-formyltetrahydrofolate, could have a significant effect on the activity of dihydrofolate reductase.
